Sareum Holdings PLC

SAR

Equity

ISIN GB00BMC3RJ87 / Valor 116566624

LSE London Stock Exchange, SETS (2024-09-18)

GBP 0.26-3.70%

Sareum Holdings PLC
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Sareum Holdings PLC is a clinical-stage biopharmaceutical company focused on the development of small molecule kinase inhibitors for the treatment of autoimmune diseases and cancer. The company's research and development efforts are centered on creating next-generation therapies that target specific kinases involved in disease pathways, aiming to provide more effective and targeted treatment options. Sareum leverages its expertise in medicinal chemistry and drug discovery to advance its pipeline of therapeutic candidates through preclinical and clinical stages, with the goal of addressing unmet medical needs in oncology and immunology.

Summarized from source with an LLMView SourceSector: Healthcare

Q4 2023 Earnings Overview

For the fourth quarter of 2023, Sareum Holdings PLC reported an earnings per share (EPS) of -£0.03, which represents a year-over-year decrease of 36.84% from the EPS of -£0.019 in the same quarter of the previous year.

Q2 2023 Financial Performance

Sareum Holdings PLC's earnings for the second quarter of 2023 were -£0.02 per share, showing a decline of 40.00% compared to -£0.015 per share in the second quarter of 2022.

Q4 2022 Results

In the fourth quarter of 2022, Sareum Holdings PLC recorded an EPS of -£0.02, which was a decrease of 35.71% from -£0.014 per share reported in the fourth quarter of 2021.

Q2 2022 Earnings Report

The second quarter of 2022 saw Sareum Holdings PLC achieving an EPS of -£0.01, marking a significant decline of 87.50% from the EPS of -£0.008 in the second quarter of 2021.

Q4 2021 Financial Highlights

Sareum Holdings PLC announced an EPS of -£0.01 for the fourth quarter of 2021, which was a substantial decrease of 133.33% from the EPS of -£0.006 in the same quarter of the previous year.

Summarized from source with an LLMView Source

Key figures

-66.2%1Y

-92.2%3Y

62.5%5Y

Performance

117%1Y

97.7%3Y

107%5Y

Volatility